Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

750.77 +4.03 (+0.54%)
Official Closing Price Updated: 7:00 PM EDT, Apr 17, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,070,429
Open 759.20
Bid (Size) 748.00 (2)
Ask (Size) 758.97 (1)
Prev. Close 746.74
Today's Range 744.88 - 771.83
52wk Range 367.35 - 800.78
Shares Outstanding N/A
Dividend Yield 0.60%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Why Eli Lilly Stock Beat the Market Today While ResMed and AdaptHealth Sank
The company published some very good news from the lab, although it wasn't so encouraging for smaller rivals. 
Via The Motley Fool
Eli Lilly and Co's Options Frenzy: What You Need to Know
Via Benzinga

Performance

YTD
+26.78%
+26.78%
1 Month
-1.56%
-1.56%
3 Month
+18.31%
+18.31%
6 Month
+23.42%
+23.42%
1 Year
+101.63%
+101.63%

More News

Read More
Eli Lilly Pops After Weight-Loss Drug Succeeds In Highly Anticipated Sleep Apnea Test
Via Investor's Business Daily
Nasdaq 100 Forecast: QQQ Inches Higher Ahead Of Fed Speakers
Via Talk Markets
Topics Economy
Exposures Interest Rates
Eli Lilly's Famed Weight Loss Drug Zepbound Works As Sleep Apnea Treatment, Successful Late-Stage Studies Show
Via Benzinga
3 Weight-Loss ETFs to Profit From the Obesity Drug Boom
Via InvestorPlace
Topics ETFs
Avalo Therapeutics' Newly Acquired Ex-Eli Lilly Drug Could Stand Out In Competitive Hidradenitis Suppurativa Market, Analyst Upgrades
Via Benzinga
These 3 Biotech Stocks Are Up 269% in 2024. Is There More to Come?
Via InvestorPlace
Healthcare Stocks Are Lagging With Big Earnings Weeks Ahead
Via Talk Markets
BTIG Research Predicts Over 118% Rally for These 3 Stocks
Via InvestorPlace
Better Buy: Bristol Myers Squibb or the Vanguard S&P 500 ETF?
Via The Motley Fool
Topics Stocks
Exposures US Equities
Better Growth Play: Merck or The Vanguard Growth Index Fund?
Via The Motley Fool
Novo Nordisk Arms Wegovy to Be a Triple Threat
Via MarketBeat
3 Magnificent Stocks That Could Double or More by 2030
Via The Motley Fool
This Vanguard ETF Has Skyrocketed 40% in 12 Months. Is It a No-Brainer Buy Right Now?
Via The Motley Fool
Topics ETFs
Why AnaptysBio Stock Zoomed Nearly 8% Higher This Week
Via The Motley Fool
Novo Nordisk's Dominance In Obesity & Diabetes Drug Market Backed by Strong Pipeline: Analyst Gives Outperform Rating
Via Benzinga
Eli Lilly Suffers Legal Loss For Its Popular Weight Loss/Diabetes Drug In Lawsuit Against Florida Compounding Pharmacy
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Novo Nordisk/Eli Lilly's Weight Loss Drugs Does Not Cause Suicidal Behaviors - After FDA, European Medicines Agency Says
Via Benzinga
Exposures Product Safety
Why Wall Street Got Even More Excited About The Glucose Monitor — And How Dexcom, Abbott Labs Stand To Benefit
Via Investor's Business Daily
7 A-Rated Aggressive Biotech Stocks to Bet On in 2024
Via InvestorPlace
Shed the Fat, Gain the Profits: 3 Weight-Loss Stocks to Own Until 2027
Via InvestorPlace
Why Roche Holdings Stock Popped Today
Via The Motley Fool
Wall Street Favorites: 3 Healthcare Stocks With Strong Buy Ratings for April 2024
Via InvestorPlace
Trillion-Dollar Trajectories: 3 Billion-Dollar Stocks With the Potential to Hit the Next Milestone
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.